Home LiteratureArticle Details
PMID: 19289613 Published · ppublish English Comment Editorial

Continuing trastuzumab beyond progression.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·Vol. 27 ·No. 12 ·2009-04-20 ·Pages 1935-7

Jahanzeb M

Abstract

暂无摘要

MeSH Terms
Antibodies, Monoclonal/therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents/therapeutic use Breast Neoplasms/drug therapy,metabolism,secondary Disease Progression Female Humans Receptor, ErbB-2/metabolism Trastuzumab
Chemicals
Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents Receptor, ErbB-2 Trastuzumab
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Jahanzeb Mohammad
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
1527-7755
DOI
10.1200/JCO.2008.20.8215
Published
2009-04-20
Epub
2009-00-16
Pages
1935-7
Language
English
Region
United States
NLM ID
8309333
Subset
IM
Corrections
CommentOn
PMID: 19289619
External Links
PubMed source DOI: 10.1200/JCO.2008.20.8215 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2